上海科技大学知识管理系统

Oncolytic viruses (OVs) have shown potential in converting a " cold " tumor into a " hot " one and exhibit effectiveness in various cancer types. However, only a subset of patients respond to oncolytic virotherapy. It is important to understand the resistance mechanisms to OV treatment in pancreatic ductal adenocarcinoma (PDAC) to engineer oncolytic viruses. In this study, we used transcriptome RNA sequencing (RNA-seq) to identify Visfatin, which was highly expressed in the responsive tumors following OV treatment. To explore the antitumor efficacy, we modified OV-mVisfatin, which effectively inhibited tumor growth. For the first time, we revealed that Visfatin promoted the antitumor efficacy of OV by remodeling the tumor microenvironment, which involved enhancing CD8 + T cell and DC cell infiltration and activation, repolarizing macrophages towards the M1 -like phenotype, and decreasing T reg cells using single -cell RNA sequencing (scRNA-seq) and flow cytometry. Furthermore, PD -1 blockade significantly enhanced OV-mVisfatin antitumor efficacy, offering a promising new therapeutic strategy for PDAC.